Clinical trials: Diabetic Nephropathy
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Diabetes Mellitus, Type 2, Diabetic Kidney Disease
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Worldwide, diabetic kidney disease (DKD) is the most common cause of chronic and end stage kidney disease. In parallel with the ever-increasing rates of obesity and type 2 diabetes (T2D), the incidence of DKD is expected to…
- Trial name
- RECOLAR (NCT04238702)
- Testing
- Empagliflozin 10 MG, Losartan 50Mg Tab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Chronic Kidney Disease Stage V
EVOO Coratina Intervention on Lipids in Non-diabetic Hypertensive Patients Undergoing Hemodialysis (EVOOC-3H)
Twenty-four non-diabetic hypertensive and hyperlipidemic patients undergoing periodic chronic hemodialysis will be enrolled for receiving extravirgin olive oil (EVOO) Coratina (12 patients) or refined olive oil (12 patients).
- Trial name
- EVOOC-3H (NCT03779529)
- Testing
- Olive oil
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione Schena
Diabetic Kidney Disease (DKD)
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group.
- Trial name
- NCT07034807
- Testing
- the traditional Chinese medicine prescription ' Shenzhuo Decoction ', basic treatment
- Where
- 5 sites in China
- Volunteers
- 228 people
- Sponsor
- Liu Hongfang
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetic Nephropathy Type 2, Type 2 Diabetes
Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy.
- Conditions
- Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis, Gingivitis
- Trial name
- NCT07498894
- Testing
- clinical periodontal measurements, serum samples, saliva samples
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Pamukkale University
Diabetic Kidney Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.
- Trial name
- NCT06666283
- Testing
- AP303 150μg
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Alebund Pharmaceuticals
Diabetic Nephropathy
Spironolactone in Diabetic Nephropathy
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d.
- Trial name
- NCT00317954
- Testing
- Spironolactone
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Steno Diabetes Center Copenhagen
Sleep Apnea, Diabetic Nephropathy Type 2
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Background: Diabetes, and especially diabetic kidney disease is associated with the development of cardiovascular disease such as calcification in the coronary arteries and heart failure.
- Conditions
- Sleep Apnea, Diabetic Nephropathy Type 2, Coronary Atheroscleroses, Heart Insufficiency
- Trial name
- SLEEP (NCT04549324)
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetic Nephropathy
Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality.
- Trial name
- NXT-DKD (NCT07698223)
- Testing
- Naoxintong Capsule
- Where
- 8 sites in China
- Volunteers
- 410 people
- Sponsor
- Chen Xiangmei
Diabetic Kidney Disease
SER150 vs Placebo in Diabetic Kidney Disease
This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either…
- Trial name
- NCT04881123
- Testing
- SER150
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Serodus AS
Diabetic Nephropathy
Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy
Diabetic kidney disease (DKD) is one of the most common microvascular complications of type 2 diabetes mellitus (T2DM), affecting up to 40% of diabetic patients and accounting for the leading cause of end-stage renal disease…
- Trial name
- NCT07173686
- Volunteers
- 80 people
- Sponsor
- Assiut University
Diabetes Mellitus
Assessment of Serum Magnesium Level with Diabetic Foot Ulceration in Type II Diabetes Associated with Diabetic Nephropathy Patients
Magnesium (Mg), is the fourth most common cation in the body, with an essential role in fundamental biological reactions, whose deficiency provokes biochemical and symptomatic alterations in the human organism.
- Trial name
- NCT06754878
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Assiut University
Chronic Kidney Disease Patients
Lipid Profile in Diabetic and Non Diabetic CKD Patients
The goal of this observational study is to compare blood lipid (fat) levels in participants with chronic kidney disease (CKD) with diabetes and without diabetes and who over 20 years old.
- Trial name
- CKD (NCT06802978)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Diabetes Mellitus Type 2
Patients With Type 2 Diabetes
Diabetes mellitus
- Trial name
- NCT07245082
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
Diabetic Nephropathies
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
The main objective of this trial is the safety and tolerability of 3 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme…
- Trial name
- NCT03165227
- Testing
- BI 685509
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathies, Diabetic Kidney Disease
Formoterol in Diabetes
The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to…
- Trial name
- NCT07022418
- Testing
- Formoterol furmarate (20 μg)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Medical University of South Carolina
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic